Vera Therapeutics Statistics
Total Valuation
VERA has a market cap or net worth of $2.26 billion. The enterprise value is $1.84 billion.
| Market Cap | 2.26B |
| Enterprise Value | 1.84B |
Important Dates
The next confirmed earnings date is Thursday, November 5, 2026, after market close.
| Earnings Date | Nov 5, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
VERA has 72.06 million shares outstanding. The number of shares has increased by 12.23% in one year.
| Current Share Class | 72.06M |
| Shares Outstanding | 72.06M |
| Shares Change (YoY) | +12.23% |
| Shares Change (QoQ) | +0.51% |
| Owned by Insiders (%) | 0.89% |
| Owned by Institutions (%) | 92.17% |
| Float | 52.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| Forward PS | 19.72 |
| PB Ratio | 5.46 |
| P/TBV Ratio | 5.48 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 10.92, with a Debt / Equity ratio of 0.19.
| Current Ratio | 10.92 |
| Quick Ratio | 10.41 |
| Debt / Equity | 0.19 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -55.18 |
Financial Efficiency
Return on equity (ROE) is -91.75% and return on invested capital (ROIC) is -50.43%.
| Return on Equity (ROE) | -91.75% |
| Return on Assets (ROA) | -46.76% |
| Return on Invested Capital (ROIC) | -50.43% |
| Return on Capital Employed (ROCE) | -85.78% |
| Weighted Average Cost of Capital (WACC) | 9.96% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.11M |
| Employee Count | 361 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, VERA has paid $1,000 in taxes.
| Income Tax | 1,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +5.31% in the last 52 weeks. The beta is 1.05, so VERA's price volatility has been similar to the market average.
| Beta (5Y) | 1.05 |
| 52-Week Price Change | +5.31% |
| 50-Day Moving Average | 32.03 |
| 200-Day Moving Average | 37.05 |
| Relative Strength Index (RSI) | 54.80 |
| Average Volume (20 Days) | 1,715,460 |
Short Selling Information
The latest short interest is 17.24 million, so 23.92% of the outstanding shares have been sold short.
| Short Interest | 17.24M |
| Short Previous Month | 17.04M |
| Short % of Shares Out | 23.92% |
| Short % of Float | 32.91% |
| Short Ratio (days to cover) | 6.93 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -415.76M |
| Pretax Income | -401.89M |
| Net Income | -401.90M |
| EBITDA | -415.22M |
| EBIT | -415.76M |
| Earnings Per Share (EPS) | -$5.89 |
Balance Sheet
The company has $499.16 million in cash and $76.91 million in debt, with a net cash position of $422.26 million or $5.86 per share.
| Cash & Cash Equivalents | 499.16M |
| Total Debt | 76.91M |
| Net Cash | 422.26M |
| Net Cash Per Share | $5.86 |
| Equity (Book Value) | 407.76M |
| Book Value Per Share | 5.67 |
| Working Capital | 479.17M |
Cash Flow
In the last 12 months, operating cash flow was -$338.65 million and capital expenditures -$258,000, giving a free cash flow of -$338.91 million.
| Operating Cash Flow | -338.65M |
| Capital Expenditures | -258,000 |
| Depreciation & Amortization | 536,000 |
| Net Borrowing | n/a |
| Free Cash Flow | -338.91M |
| FCF Per Share | -$4.70 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
VERA does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -12.23% |
| Shareholder Yield | -12.23% |
| Earnings Yield | -18.76% |
| FCF Yield | -15.20% |
Analyst Forecast
The average price target for VERA is $74.20, which is 136.23% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $74.20 |
| Price Target Difference | 136.23% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 15 |
| Revenue Growth Forecast (3Y) | n/a |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |